Advion Reaches OEM, Distribution Deal with CAMAG for TLC/MS Interface Product | GenomeWeb

NEW YORK (GenomeWeb News) – Advion said on Monday it has signed an exclusive original equipment manufacturing and distribution partnership deal with Swiss firm CAMAG for Advion's TLC/MS interface product.

The two companies plan to commercialize a combined system to Advion's Synthetic Organic Chemistry and Peptide Synthesis global market segments, Advion said, adding it has exclusive marketing and support rights in certain geographies, including North America and parts of Europe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.